

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/HCBB19E53019EN.html>

Date: July 2022

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: HCBB19E53019EN

Abstracts

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Hepatocyte Growth Factor - Drugs In Development, 2022'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 19 molecules. Out of which approximately 19 molecules are developed by Companies.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor - Drugs In Development, 2022' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications,

stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 4, 1, 6 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Dermatology, Genetic Disorders, Hematological Disorders and Respiratory which include indications Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Glioblastoma Multiforme (GBM), Melanoma, Ovarian Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Spinal Cord Injury, Alzheimer's Disease, Anxiety Disorders, Arteriosclerosis, Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Colorectal Cancer, Dementia, Depression, Diabetic Ischemic Foot Ulcers, Diabetic Neuropathic Pain, Diabetic Peripheral Neuropathy, Gallbladder Cancer, Gastric Cancer, Hepatocellular Carcinoma, Intermittent Claudication, Leiomyosarcoma, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Lung Injury, Lymphedema, Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Cancer, Myocardial Infarction, Nasopharyngeal Cancer, Neuromuscular Disorders, Non-Small Cell Lung Cancer, Occlusive Arterial Disease (OAD), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral Artery Occlusive Disease (PAOD), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Scar, Schizophrenia, Solid Tumor, Thromboangiitis obliterans (Buerger disease) and Ulcers.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and

universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Companies

Involved in Therapeutics Development

AnGes Inc

Athira Pharma Inc

AVEO Pharmaceuticals Inc

Beijing SH biotechnology Co Ltd

G&P Bioscience Co Ltd

Helixmith Co Ltd

i2 Pharmaceuticals Inc

Kringle Pharma Inc

Minerva Biotechnologies Corp

Molecular Partners AG

PlateletBio

Yichang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Drug Profiles

Ad-HGF - Drug Profile

Product Description

Mechanism Of Action

ATH-1020 - Drug Profile

Product Description

Mechanism Of Action

History of Events

bepmerinogene perplasmid - Drug Profile

Product Description

Mechanism Of Action

History of Events

donaperminogene seltoplasmid - Drug Profile

Product Description

Mechanism Of Action

History of Events

ficlatuzumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

fosgonimeton - Drug Profile

Product Description

Mechanism Of Action

History of Events

GB-102 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate HGF for Liver Fibrosis - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to activate HGF for Lung Injury - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate HGF for Neuro Muscular Disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to activate HGF for Peripheral Artery Occlusive Disease - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile

Product Description

Mechanism Of Action

MP-0250 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NK-4 - Drug Profile

Product Description

Mechanism Of Action

History of Events

orempermin alfa - Drug Profile

Product Description

Mechanism Of Action

History of Events

SL-186 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SL-188 - Drug Profile

Product Description

Mechanism Of Action

History of Events

YYB-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Product Development Milestones

Featured News & Press Releases

Jul 25, 2022: Athira Pharma to present clinical and preclinical data at Alzheimer's Association International Conference 2022

Jun 22, 2022: Athira Pharma announces topline results from ACT-AD Phase 2 proof of concept study of Fosgonimeton in mild-to-moderate Alzheimer's disease

May 09, 2022: Athira Pharma extends ongoing open label extension study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for mild to moderate Alzheimer's Disease

May 02, 2022: Helixmith announces VM202 (Engensis) presentation at New York Academy of Sciences 'Advances in Pain' Meeting on May 3, 2022

Apr 05, 2022: Athira doses first subject in Phase I neuropsychiatric treatment trial

Mar 30, 2022: Athira Pharma highlights strong execution of strategy and positioning for the future

Mar 20, 2022: Athira Pharma presents study overview and baseline data from ACT-AD phase 2 trial of Fosgonimeton in mild-to-moderate Alzheimer's Disease at the 2022 AD/PD Congress

Mar 14, 2022: Athira Pharma to present overview and update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease at AD/PD 2022 Congress

Mar 14, 2022: Paper reporting results from Helixmith's phase 3 gene therapy trial for painful diabetic neuropathy was one of the top-10 most-downloaded articles in Clinical and Translational Science

Feb 22, 2022: Athira Pharma to present preclinical data at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting

Feb 22, 2022: Athira Pharma to present preclinical data of fosgonimeton at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting

Feb 22, 2022: Athira Pharma announces publication of phase 1 results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease

Jan 25, 2022: Athira Pharma announces initiation of patient dosing in SHAPE, a phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's Disease dementia and dementia with lewy bodies

Dec 09, 2021: Kringle Pharma announces last patient out in phase 2 study of KP-100IT for the treatment of ALS

Nov 10, 2021: Athira Pharma presents overview and update from ACT-AD and LIFT-AD trials of ATH-1017 in mild-to-moderate Alzheimer's disease at CTAD Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AnGes Inc, 2022

Pipeline by Athira Pharma Inc, 2022

Pipeline by AVEO Pharmaceuticals Inc, 2022

Pipeline by Beijing SH biotechnology Co Ltd, 2022

Pipeline by G&P Bioscience Co Ltd, 2022

Pipeline by Helixmith Co Ltd, 2022

Pipeline by i2 Pharmaceuticals Inc, 2022

Pipeline by Kringle Pharma Inc, 2022

Pipeline by Minerva Biotechnologies Corp, 2022

Pipeline by Molecular Partners AG, 2022

Pipeline by PlateletBio, 2022

Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2022

Pipeline by Yooyoung Pharm Co Ltd, 2022

Dormant Products, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/HCBB19E53019EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HCBB19E53019EN.html>